B cell activating factor receptor (BAFFR)

The term "B cell survival" is not itself a molecular target, but refers to the biological process regulated by several key molecules. The most prominent molecular target associated with "B cell survival" is the B cell activating factor receptor (BAFFR), encoded by the TNFRSF13C gene. This membrane-bound receptor binds to its ligand, BAFF, a cytokine essential for the maturation and maintenance of peripheral B cells. Signaling through BAFFR activates downstream pathways including NF-kappaB, PI3K/AKT, and MAPK/ERK that promote mitochondrial stability and protein synthesis in transitional, follicular, and marginal zone B cells[1][2][3]. Therapeutic agents such as belimumab inhibit this pathway by neutralizing soluble BAFF rather than directly targeting the receptor; atacicept blocks both BAFF and APRIL ligands. These interventions are used primarily in autoimmune conditions like systemic lupus erythematosus but can also impact malignancies where aberrant activation of this axis supports tumor growth. Deficiency or blockade of this pathway leads to profound loss of mature peripheral B cells while sparing certain innate-like subsets such as peritoneal B1 cells[1]. Overactivation contributes to autoimmunity. The query "B cell survival" does not refer to a single molecule or canonical drug target but rather describes a cellular process governed mainly by receptors such as BAFFR, along with others like BCMA and TACI. For structured data purposes related to drug discovery or pharmacology databases, it is more accurate to use "B cell activating factor receptor" (BAFFR) as the canonical name for this target class[1][2].

Other names

BAFF receptorTNFRSF13CBLyS receptorCD268

Inhibition of BAFF/BAFFR interaction reduces B cell survival and differentiation by blocking pro-survival signaling pathways[1][2][3].